Journal of Carcinogenesis & Mutagenesis

Journal of Carcinogenesis & Mutagenesis
Open Access

ISSN: 2157-2518

Shojiro Kikuchi

Department of Surgery, Institute for Advanced Medical Science, Hyogo College of Medicine, Nishinomiy, Japan

  • Review Article   
    Prospective Anticancer Therapy for CCL2-CCR2 Pathway Inhibition using Propagermanium
    Author(s): Shojiro Kikuchi* and Takahito Jomori

    Cancer stromal interactions have an essential role in the development and progression of most cancers. Cancer cells utilize the host's immune system for growth, invasion, survival, and metastasis. Because the CCL2 (chemokine (C-C-motif) ligand 2–CCR2 (C-C chemokine receptor type 2 pathway consists of a major inflammatory chemokine and receptor, various studies have been conducted to suppress cancer metastasis via this pathway. Many studies have indicated that the migration of tumor-associated macrophages (TAM) and monocytic bone marrow-derived suppressor cells (Mo-MDSCs) from the bone marrow into the microenvironment known as the "niche", which utilizes the CCL2–CCR2 pathway, promotes cancer metastasis. In line with this strategy, CCL2-neutralizing antibody CNTO888 (Carlumab), anti-CCR2 antibody (MLN1202, plozalizumab), and CCR2 antagonist (CCX872-.. Read More»

    Abstract HTML PDF